What do systematic reviews say?

Endolymphatic sac decompression vs placebo (sham surgery)

The review found no eligible studies for this question.

• Surgical interventions for Ménière’s disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dietary intervention (probiotics) vs placebo

The review found no eligible studies for this question.

• Non‐pharmacological interventions for prophylaxis of vestibular migraine 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

CBT vs no treatment

The review found no eligible studies for this question.

• Non‐pharmacological interventions for prophylaxis of vestibular migraine 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Triptans vs placebo

• Pharmacological interventions for acute attacks of vestibular migraine 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 114 participants
  Very low

Vestibular rehabilitation vs placebo or no treatment

The review found no eligible studies for this question.

• Non‐pharmacological interventions for persistent postural‐perceptual dizziness (PPPD) 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

tDCS vs placebo

• Non‐pharmacological interventions for persistent postural‐perceptual dizziness (PPPD) 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

Talking therapies or stress management vs placebo or no treatment

The review found no eligible studies for this question.

• Non‐pharmacological interventions for persistent postural‐perceptual dizziness (PPPD) 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

C1 esterase inhibitor vs placebo or active control

C1 esterase inhibitor showed no clear difference in adverse events (during compared with placebo or active control (moderate certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.03 [0.84, 1.27]
  1 study · 44 participants
  Moderate

Nanofiltered C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Avoralstat vs placebo

Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.85 [0.62, 1.16]
  1 study · 24 participants
  Low

Palmitoylethanolamide and luteolin vs no intervention

• Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 12 participants
  Very low

Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention

• Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 18 participants
  Very low

Intranasal steroid spray vs placebo or no intervention

• Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 77 participants
  Very low

Oral hydroxychloroquine vs placebo

Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 3.9 [0.19, 78.46]
  1 study · 71 participants
  Moderate

Oral dehydroepiandrosterone vs placebo

Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 0.09 [0.01, 1.66]
  1 study · 381 participants
  Moderate

Oral chloroquine vs placebo

Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.45]
  1 study · 24 participants
  Low

Oral ciclosporin vs azathioprine (AZA)

Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 0.89 [0.48, 1.65]
  1 study · 89 participants
  Low

Oral methotrexate vs oral chloroquine

Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 1.73 [0.27, 11.07]
  1 study · 41 participants
  Low

Oral methotrexate vs placebo

Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).

• Interventions for cutaneous disease in systemic lupus erythematosus 2021 · Cochrane Headline outcomes only
  RR 12.05 [0.69, 211.36]
  1 study · 86 participants
  Moderate

IM erythropoietin vs oral placebo

The review found no eligible studies for this question.

• Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found